There are 749 resources available
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Presenter: Thanyanan Reungwetwattana
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Invited Discussant 475O, LBA16 and LBA17
Presenter: Pilar Garrido Lopez
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Presenter: Myung-Ju Ahn
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
Presenter: Yi-Long Wu
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
Presenter: Dae Ho Lee
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC
Presenter: Laura Mezquita
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
Presenter: Daniel Shao Weng Tan
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours
Presenter: Do-Youn Oh
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study
Presenter: Niels Reinmuth
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib
Presenter: Yasushi Goto
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast